Intelligence Evolves. Matter Follows.

Jeff Riley is Co-Founder and Chief Executive Officer of Amphora Labs, with more than 25 years of leadership and operating experience across biotechnology, pharmaceuticals, and artificial intelligence. His expertise spans corporate strategy, business development, strategic alliances, joint ventures, and financing, with experience building emerging companies and working within global pharmaceutical organizations.

Throughout his career, Jeff has raised more than $1.5 billion through private and public equity and debt financing and helped lead three companies to initial public offerings. He has negotiated global strategic alliances, established joint ventures, and led venture and public financings to accelerate product development. His executive experience includes CEO, chief business officer, chief financial officer, chief operating officer, chairman, and business development leadership roles. His career spans AvMax, Ontogen, Amphora RTP, Synthetic Biologics, Gain Therapeutics, BlinkCNS, and Caravan Biologix, alongside experience at Pfizer, SmithKline Beecham, and Quest Diagnostics.

Jeff also brings venture capital experience with Queensland Investment Corporation and the Queensland Biocapital Fund, complemented by international operating experience across the United States, Latin America, Europe, Australia, and Turkey. He holds degrees from Boise State University, Arizona State University, and Thunderbird.

Alex Boches is Co-Founder and Chief Product Officer of Amphora Labs, with 15 years of experience building and commercializing businesses across technology, artificial intelligence, and biotechnology. At Amphora, he leads product strategy, scientific use-case development, and customer discovery, alongside business operations, strategic partnerships, and fundraising.

Previously, Alex co-founded and served as CEO of Teal Omics, a Stanford University spinout applying proteomics and AI to drug discovery. He led technology transfer negotiations, raised pre-seed and seed capital, built the research team, and initiated a drug discovery program targeting neurodegenerative disease. As US General Manager and COO of Baze Labs, he built the US business, developed partnerships with CVS, Walgreens, and Kroger Health, and worked with the CEO to negotiate and execute its acquisition by Nature’s Way. Earlier, he helped establish Quid’s healthcare and life sciences business, commercializing enterprise analytics for pharmaceutical customers including Pfizer, Novartis, UCB, and Boehringer Ingelheim.

Alex also served as a Partner at Form Life Ventures, where he helped define the firm’s longevity and precision health investment strategy and led the incubation of Teal Omics. His broader commercial executive and advisory work spans fundraising, market entry, and growth strategy for technology, AI, and biotechnology companies. He holds a BA in Chemistry from Colby College.

Adam Breashears is Co-Founder and Chief Technology Officer of Amphora Labs, with more than 25 years of experience in software engineering, automation, enterprise platforms, and autonomous systems. He leads engineering for Amphora’s AI-assisted discovery platform, combining machine learning, knowledge graphs, data provenance, and human oversight to help scientific experts explore complex product spaces.

Adam’s expertise spans large language models, agentic systems, retrieval, distributed systems, infrastructure automation, and production software architecture. Across roles at NYSE Euronext, PICO Quantitative Trading, Citadel, Mangata Networks, and Metis, he has built systems that automate software delivery, map operational dependencies, and coordinate infrastructure. At NYSE Euronext, his work helped increase release throughput from approximately two releases per weekend to as many as 50 per night. At PICO, he developed a graph-based approach to infrastructure orchestration and customer-impact analysis. At Metis, he built AI platform capabilities for regulated financial workflows, combining multi-hop reasoning, retrieval, and enterprise data access.

Adam’s experience combines hands-on development with architecture, engineering leadership, and the operational design needed to scale complex systems. He holds an MS in Applied Data Science from the University of Chicago, an MBA in Entrepreneurship from DePaul University, and a BS in Finance from Louisiana Tech University.

Wes Spence is Co-Founder and Vice President of Partnerships at Amphora Labs, where he leads strategic growth and partnership development across defense, energy, and manufacturing. A retired US Navy SEAL Captain, he brings a 25-year Navy career and 13 years of global performance consulting experience. His work at Amphora spans joint development partnerships, defense capture, government contracts, grants, and other transaction agreements, advancing materials-science opportunities from customer problem definition toward field pilots.

At CAVU International, Wes held senior roles in business development and coaching performance. He led the company’s expansion into manufacturing with John Deere and Alpek Polyester, generating more than $3 million in total sales, and developed the coaching methodology used by 100 coaches worldwide. He also managed consulting teams supporting four Alpek manufacturing facilities and more than 1,000 employees. Earlier, he founded Spence Global Solutions and worked with Check-6, advising organizations on leadership, safety, process improvement, and operational performance.

During his Navy career, Wes commanded the Naval Special Warfare Advanced Training Command and directed worldwide operations and training for Naval Special Warfare. He holds an MS in Information Technology Management from the Naval Postgraduate School and a BS in Physical Science from the United States Naval Academy.